Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
?2.50
 
WKN: A140QA / Name: Canopy Growth / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Canopy Growth Corp Stock

Our community is currently high on Canopy Growth Corp with 4 Buy predictions and 0 Sell predictions.
With a target price of 2 € there is potential for a 326.44% increase which would mean more than doubling the current price of 0.47 € for Canopy Growth Corp.
Our community identified positive and negative aspects for Canopy Growth Corp stock for the coming years. 3 users see the criterium "Business model" as a plus for the Canopy Growth Corp stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Canopy Growth Corp in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Canopy Growth Corp vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Canopy Growth Corp - - - - - - -
Bausch Health Companies Inc. 1.000% 1.036% 15.129% -1.419% 19.568% -66.694% -58.554%
Catalent Inc. -0.380% -1.667% 7.273% -17.674% 28.883% -43.810% 39.078%
Opko Health Inc. 0.260% 2.411% -3.558% -13.106% -35.326% -75.319% -59.579%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Based on a first impression of the financials of Canopy Growth, a leading company in the pharmaceutical industry, it is evident that the company has faced some difficulties in recent years. With net losses reported in the last three years and a negative gross profit, the company appears to be struggling in terms of revenue generation and operational efficiency. However, there are still positive aspects such as a strong cash position and a manageable level of debt. The following in-depth analysis highlights the pros and cons of Canopy Growth's financial performance to better understand its overall position in the market.

*Pros: *

Significant cash and short-term investments: Canopy Growth has a strong cash position, as shown by the most recent quarterly balance sheet, which reports CAD 769.5 million in cash and short-term investments amounting to CAD 1.22 billion. This provides financial stability and the flexibility to pursue growth opportunities or address unforeseen challenges.

Comments

Buy Canopy Growth Corp
Show more

Buy Canopy Growth Corp
Show more

Buy Canopy Growth Corp
Show more